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Abstract: In this study, a liposomal lyophilized powder formulation of panomycocin was 
developed for therapeutic purposes against vulvovaginal candidiasis which affects 80% of 
women worldwide. Panomycocin is a potent antimycotic protein secreted by the yeast 
Wickerhamomyces anomalus NCYC 434. This study involved the preparation of panomycocin-
loaded stratum corneum lipid liposomes (SCLLs), characterization of the SCLLs, and determina-
tion of antimycotic efficacy of the formulation against Candida albicans and Candida glabrata 
clinical vaginal isolates in a human vaginal epithelium tissue model. The encapsulation and 
loading efficiencies of SCLLs were 73% and 76.8%, respectively. In transmission electron 
microscopy images, the SCLLs appeared in the submicron size range. Dynamic light scattering 
analyses showed that the SCLLs had uniform size distribution. Zeta potential measurements 
revealed stable and positively charged SCLLs. In Fourier transform infrared spectroscopy 
analyses, no irreversible interactions between the encapsulated panomycocin and the SCLLs 
were detected. The SCLLs retained .98% of encapsulated panomycocin in aqueous solution 
up to 12 hours. The formulation was fungicidal at the same minimum fungicidal concentration 
values for non-formulated pure panomycocin when tested on an in vitro model of vaginal can-
didiasis. This is the first study in which SCLLs and a protein as an active ingredient have been 
utilized together in a formulation. The results obtained in this study led us to conduct further 
preclinical trials of this formulation for the development of an effective topical anti-candidal 
drug with improved safety.
Keywords: antifungal protein, panomycocin, exo-β-1,3-glucanase, stratum corneum lipid 
liposome, vulvovaginitis, Candida spp.
Introduction
Vulvovaginal candidiasis is a yeast infection which affects 80% of women of 
childbearing ages worldwide at least once in their lifetime. Candida albicans strains 
are the major pathogens isolated from the vagina of patients with vulvovaginal 
candidiasis.1 Almost all of the remaining strains (10% of the total) belong to Candida 
glabrata species while Candida tropicalis, Candida parapsilosis, and Candida krusei 
strains are also associated with this infection very rarely.2 Candida spp. multiply by 
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adhering to the stratum corneum layer of the epithelium in 
the infected vaginal tissue.2,3 In 40%–50% of the cases, recur-
rence is seen with 8%–10% risk of becoming chronic which 
may then develop into life-threatening invasive Candidiasis 
infection.4 In the current treatment of vulvovaginal candidi-
asis, antimycotic agents such as azoles, polyenes, allylam-
ines, echinocandins, and antimetabolites are commonly 
used.5 Resistance of pathogens to antimycotic drugs, mild 
to serious adverse effects such as gastrointestinal distur-
bances and hepatotoxicity caused by these drugs, and drug 
interactions in immunosuppressed patients are the known 
major complications associated with the current therapies.5 
Also, some active ingredients that can be used in treatments 
(such as amphotericin B and Ciclopirox olamine)6,7 are 
optimally effective at neutral pH values in laboratory con-
ditions.8 Healthy women have an acidic vaginal pH in the 
range of 3.7–5.7 worldwide9 which remains unchanged in 
 vulvovaginal candidiasis.10,11 Thus, to achieve high efficacy 
in acidic environments, large doses of previously mentioned 
active ingredients are required in clinical conditions. For 
the previously mentioned reasons, there is a continuing 
need for new classes of antimycotic agents that have little 
or no toxicity toward mammalian cells and a low tendency 
to elicit resistance.5 Among the different approaches, natu-
rally produced antifungal/antimycotic proteins are attracting 
increasing attention. In various studies, panomycocin, which 
is produced and secreted into the environment by the killer 
(K+) yeast strain Wickerhamomyces anomalus (formerly 
known as Pichia anomala) NCYC 434, has been shown as 
a promising potential antifungal agent in biomedicine.12–14 
Panomycocin is a 49 kDa monomeric glycoprotein with an 
exo-β-1,3-glucanase activity. It hydrolyzes the exo-β-1, 
3-glucans which are vital polymers for the integrity of the 
fungal cell wall, leading to the disruption of the cell wall 
and death of the target cells.13 The mammalian cells lack the 
β-1,3-glucans in their structure, and this highlights the use 
of panomycocin as a selective antifungal/antimycotic agent 
in therapy. In several studies, the potent in vitro antifungal 
activity of panomycocin against human dermatophytes and 
Candida spp. was shown.15,16 In solution, panomycocin is 
stable and active at the pH range between 3.0 and 5.5 up 
to 37°C.12,13 In lyophilized form, it retains its stability and 
activity up to 38.5°C (unpublished data) and in the vaginal 
pH range.
The most common formulation type for the topical delivery 
of proteins for therapeutic purposes is their encapsulation in 
carrier systems which will allow the retention of protein 
integrity and activity. Being biocompatible, biodegradable, 
and nontoxic, liposomes are among the most preferable pro-
tein carrier systems in therapeutic applications.17,18
Liposomes with lipid composition similar to that of lipid 
matrix of the stratum corneum layer of the epithelium are 
referred to as stratum corneum lipid liposomes (SCLLs) 
and are virtually devoid of phospholipids commonly used in 
conventional liposomes.19 SCLLs adhere to the surface of the 
stratum corneum layer of the epithelium and integrate into the 
stratum corneum structure, releasing the encapsulated active 
ingredient.20,21 In literature, there are studies with SCLLs car-
rying non-proteinaceous substances.21,22 To the best of our 
knowledge, this is the first report describing the encapsulation 
of a protein in SCLLs in the biologically active form.
Efficacy evaluations of the topical formulations by 
alternative (non-animal) methods such as the use of 3-D 
tissue constructs which exhibit in vivo-like morphological 
and ultrastructural characteristics have significantly contrib-
uted to the minimization of animal utilization for ethical23 
and cost reduction purposes. In vitro reconstructed human 
vaginal epithelium (HVE) tissue models have been recently 
utilized and shown to be valuable tools for assessing the 
efficacy of topically applied gynecological compounds 
and products.24
In the present study, a topical liposomal lyophilized 
powder formulation of panomycocin was developed for 
therapeutic purposes against vulvovaginal candidiasis. This 
study involved the preparation of SCLLs and the encapsula-
tion of panomycocin, characterizations of the formulation, 
and the biological activity tests on HVE tissue model infected 
with C. albicans and C. glabrata clinical vaginal isolates.
Materials and methods
strains and growth media
W. anomalus from the National Collection of Yeast Cultures, 
UK (NCYC 434, K+) was used as the source of panomycocin 
and maintained on YEPD agar (yeast extract [Sigma-Aldrich 
Co., St Louis, MO, USA] 1% [w/v], peptone [Sigma-Aldrich 
Co.] 2% [w/v], dextrose [Sigma-Aldrich Co.] 2% [w/v], 
and agar [EMD Millipore, Billerica, MA, USA] 2% [w/v], 
pH 5.5). Candida strains (four in total; three C. albicans and 
one C. glabrata vaginal isolates) were from German Hospital, 
İstanbul, Turkey and maintained on Sabouraud dextrose agar 
(SDA) (peptone [Sigma-Aldrich Co.] 2% [w/v], dextrose 
[Sigma-Aldrich Co.] 2% [w/v], and agar [EMD Millipore] 
2% [w/v], pH 5.6). The identity of all isolates was confirmed 
by MALDI-TOF mass spectroscopic species identification 
technique (MALDI Biotyper, Bruker Corporation, Billerica, 
MA, USA) according to the manufacturer’s instructions.
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Production and purification of 
panomycocin
Panomycocin-producing strain W. anomalus NCYC 434 
was cultured in 5 L of YEPD at 20°C until the stationary 
phase in a 7 L bioreactor (BioBundle; Applikon, Delft, 
the Netherlands) at an impeller speed of 450 rpm. The 
pH of the culture medium was maintained at 4.5 by auto-
matic addition of 2 M KOH (ADI 1030 Bio-Controller; 
 Applikon). The culture chamber was fed with sterilized 
air by a mass-flow control unit with a flow rate of 2 L/min 
to ensure dissolved oxygen concentration above 30% 
measured by Applikon oxygen probe. The culture medium 
was clarified by centrifugation (5,000 rpm for 10 min 
at 4°C) and filtered through 0.45 and 0.2 µm cellulose 
acetate membranes (Sartorius AG, Göttingen, Germany). 
Panomycocin in the cell-free medium was concentrated 
by ultrafiltration using 30 and 5 kDa cut-off ultrafilters 
(Vivaflow200; Sartorius AG).
The crude panomycocin was purified and analyzed as 
described previously.12 The biological activity of the pure 
panomycocin was tested on vaginal C. albicans and C. 
glabrata isolates using the microdilution broth method 
according to the Clinical and Laboratory Standards Insti-
tute reference document M27-A325 with modifications 
(assay medium pH was adjusted to 4.5 and the assay was 
performed at 30°C).
Preparation of sclls and encapsulation 
of panomycocin in the vesicles
A lipid mixture similar to the composition of the stratum 
corneum was prepared as described by Wertz et al.26 
Ceramide:cholesterol:palmitic acid:cholesteryl sulfate 
were combined in 4:2.5:2.5:1 ratio (w/w). For the construc-
tion of positively charged vesicles, stearylamine (18% by 
mole) was added to the mixture,27 and as an antioxidant, it 
was supplemented with alpha tocopherol (3% by mole)28 
(chicken egg ceramide was from Avanti Lipids, Alabaster, 
AL, USA and all other lipids and chemicals were from 
Sigma-Aldrich Co.). From this mixture, empty liposomes 
were prepared by thin film hydration method of Bangham 
et al29 with modifications. The lipid mixture was dissolved 
in chloroform-methanol (2:1 v/v) to yield a lipid concen-
tration of 10 mg/mL. Then, the solvent was removed in a 
rotary evaporator (Steroglass, Perugia, Italy) at 25°C and 
40 rpm under vacuum (525 mmHg) until a homogeneous 
thin film was formed (~10 min). It was further incubated 
at the same conditions in the absence of vacuum for 2 h, 
and any remaining solvent was removed with nitrogen 










 in a water bath (95°C) under vigorous agitation 
(120 rpm). Sterile glass beads (426–600 microns; Sigma-
Aldrich Co.) were also included to aid the removal of the 
lipid film from the inner surface of the flask in the course 
of agitation. The resulting milky liposome dispersion was 
bath-ultrasonicated (Isolab, Wertheim, Germany) at 95°C, 
40 Hz, 180 W for 15 min.
Panomycocin was encapsulated in SCLL vesicles by the 
freeze-thaw technique described by Zhao and Lu30 with minor 
modifications. Briefly, liposome dispersion (0.95 mg/mL) 
and purified panomycocin solution (2 mg/mL) were mixed 
in 2:1 ratio (v/v). This mixture was rapidly frozen in liquid 
nitrogen (-196°C) for 5 min and slowly thawed at 4°C for 
40 min in a vacuum desiccator. The freeze-thaw cycle was 
repeated three times. An adequate volume of the resulting 
dispersion was aliquoted for further analyses of encapsulation 
and loading efficiencies. The free panomycocin was separated 
from the remaining dispersion by a combined ultrafiltration/
centrifugation technique at 2,500 rpm for 15 min (Centrisart I, 
100 kDa cut-off, polyethersulfone membrane; Sartorius AG) 
at 4°C. An adequate volume of the resulting panomycocin-
loaded liposomal dispersion was stored at 4°C for further zeta 
potential and dynamic light scattering (DLS) analyses which 
require liquid samples. The rest of the loaded liposomal 
dispersion was lyophilized at -115°C, 80 Torr (Maxi-Dry 
LYO; Thermo Fisher Scientific, Waltham, MA, USA) and 
stored at 4°C.
Determination of encapsulation efficiency 
(EE) and loading efficiency (LE)
EE and LE were calculated after the determination of the 
concentration of non-encapsulated panomycocin in the 
liposomal dispersion. The free panomycocin was separated 
from the loaded SCLL dispersion (1.5 mL) by a combined 
ultrafiltration/centrifugation technique as described previ-
ously, and the concentration of free panomycocin in the 
supernatant was determined according to Bradford31 in a 
nanodrop spectrophotometer (Biodrop, Cambridge, UK). The 
assay was done in triplicate. EE and LE calculations were 
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Total panomycocin is the amount of panomycocin 
(by weight) added to the liposome dispersion during 
encapsulation.
Total liposome is the amount of lipids (by weight) pres-
ent in the liposome dispersion during encapsulation. From 
the loaded SCLL dispersion, 1.5 mL aliquots were used for 
both EE and LE calculations.
characterization of the empty and the 
panomycocin-loaded sclls
The morphology and size of the empty and the panomycocin-
loaded SCLLs were examined with high contrast transmis-
sion electron microscope (TEM) (FEI Tecnai G2 Spirit 
BIOTWIN; Thermo Fisher Scientific) at an acceleration 
voltage of 80 kV.
The stability and surface charge of empty and loaded 
liposomal colloidal systems were determined with zeta 




-citric acid buffer, pH 4.0 




 at 25°C with Malvern Nano ZS90 
(Malvern Instruments, Malvern, UK). 
Investigation of irreversible intermolecular interactions 
between encapsulated panomycocin and SCLLs was done by 
Fourier transform infrared spectroscopy. Lyophilized empty 
and panomycocin-loaded SCLLs were scanned over a wave 
number range of 4,000–400 cm-1 by a Bruker Corporation 
IFS 66/S spectrometer.
Hydrodynamic size and polydispersity index of empty and 
panomycocin-loaded SCLLs were determined by DLS technique 









 at 20°C with a 90° scattering angle using a Malvern 
CGS-3 multi-angle goniometer (Malvern Instruments).
In vitro release studies of panomycocin-loaded SCLLs 
were done based on the Franz diffusion cell technique.33 
Donor and receiver chambers of the cell were separated by 
a 100 kDa cut-off membrane (EMD Millipore). Lyophilized 
liposomal powder containing 1.5 mg panomycocin was 
rehydrated in 2 mL of sterile distilled water and loaded into 
the donor chamber. The receiver chamber (5 mL) was com-
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. The system was incubated at 
37°C for 12 h with slow agitation and 1 mL of the medium 
from the receiver chamber was removed and replaced with 
fresh buffer solution at 1 h intervals. The assay was done in 
triplicate. The percentage of released protein in each sample 
was determined and plotted against time to generate in vitro 
release profile of SCLLs.
Determination of antimycotic efficacy of 
panomycocin-loaded lyophilized sclls
The antimycotic efficacy of panomycocin was tested on a 
commercially available reconstructed HVE (Episkin, Lyon, 
France) based on the vulvar epidermoid carcinoma cell 
line A431 which forms a 3-D epithelial tissue similar to 
the human in vivo vaginal mucosa when cultivated in vitro on 
a polycarbonate filter in a chemically defined medium. 
Tissues were inoculated separately with the C. albicans and 
C. glabrata vaginal isolates (1×103–5×103 CFU/mL)25 and 
incubated at 37°C for 2 h in a humidified CO
2
 incubator to 
enable the pathogens to adhere to the surface of the tissues. 
Then, three different amounts of liposomal lyophilized pow-
der containing panomycocin which correspond to 1×, 1.5×, 
and 2× minimum fungicidal concentration (MFC) values of 
non-formulated pure panomycocin for each Candida spp. 
were applied onto the surface of infected tissues (Table 1). 
After further incubation for 48 h at the previously men-
tioned conditions, the growth of each Candida strain on the 
tissues was determined by a magnifying glass in comparison 
with the control groups (growth control, sterility control, 
and negative control). Swab samples were taken from the 
tissue inserts with no visible growth and sub-cultured onto 
SDA plates for 7 days at 37°C to ascertain the killing effect 
of SCLL-encapsulated panomycocin.
Table 1 The amount of liposomal panomycocin applied onto the infected hVe tissues for each Candida spp. and the corresponding 
MFc values for non-formulated pure panomycocin
Species Amount of 
SCLL powder 
applied (mg)
Amount of panomycocin 
in the SCLL powder 
applied (µg)
Corresponding MFC 
values for non-formulated 
pure panomycocin16
Candida albicans 5.5 8 1×
8.3 12 1.5×
11 16 2×
Candida glabrata 1.4 2 1×
2.1 3 1.5×
2.8 4 2×
Abbreviations: hVe, human vaginal epithelium; MFc, minimum fungicidal concentration; scll, stratum corneum lipid liposome.
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Results
The pure panomycocin was encapsulated in SCLLs by freeze-
thawing of the liposome–protein mixture. Encapsulation and 
LE studies were performed in 1.5 mL of liposome dispersion. 
The non-encapsulated panomycocin was separated from 
the liposomal dispersion as described in “Determination of 
encapsulation efficiency (EE) and loading efficiency (LE)” 
section, and the amount of free panomycocin was found to be 
270.6 µg as determined by Bradford assay. The percentage 
of panomycocin incorporated in SCLLs relative to the initial 
total amount of panomycocin in the solution [EE% =100× 
(1,000 µg - 270.6 µg)/1,000 µg] was 73.0%, and the percent-
age of panomycocin incorporated in SCLLs relative to the 
content of the total lipid in 1.5 mL of liposome dispersion 
[LE% =100× (1,000 µg - 270.6 µg)/950 µg] was 76.8%.
Empty and panomycocin-loaded SCLLs appeared as 
spherical particles in submicron size range in TEM images 
(Figure 1A and B). DLS experiments showed monodisperse 
size distribution for each SCLL sample in the dispersion as 
indicated with their polydispersity index values approach-
ing zero. These experiments also showed that the hydrody-
namic sizes were larger than the static sizes observed with 
TEM (Table 2; Figure 2). Empty and panomycocin-loaded 
SCLLs were stable and had positively charged surfaces as 
determined by a zeta potential value of +22.0 and +21.4 mV, 
respectively (Figure 3A and B). Also, no obvious irrevers-
ible interactions were observed between the liposome 
particles and panomycocin when the infrared spectra of 
both empty and loaded SCLL samples were compared 
(Figure 4A and B). In vitro release studies showed that 
the liposomal preparation retained 98.29% of the initially 
encapsulated panomycocin in 12 h in buffer solution with a 
plateau time of 4 h (Figure 5). 
The in vitro antimycotic efficacy of the liposomal pano-
mycocin formulation was tested on HVE tissues. The tissues 
that were infected separately with the vaginal isolates of C. 
albicans and C. glabrata were observed visually with the 
aid of a magnifying glass after 48 h of incubation and com-
pared to the cream-colored and shiny candidal growth in the 
growth control wells. Candidal growth was not observed on 
the tissues in any of the inserts which contained liposomal 
lyophilized powder with predetermined panomycocin quanti-
ties which correspond to 1×, 1.5×, and 2× MFC values of 
non-formulated pure panomycocin for each Candida spp. 
(Figure 6A and B). There was also no cell growth at the end 
of 7 days of incubation for any of the strains, after the swab 
samples taken from the tissue inserts with no visible candidal 
growth were sub-cultured on SDA plates.
Discussion
In the present study, we have developed a liposomal lyo-
philized powder formulation of panomycocin for the treat-
ment of human vulvovaginal candidiasis. We have isolated 
panomycocin from the culture supernatant of W. anomalus 
NCYC 434 cells in crude form and purified it by using an 
fast protein liquid chromatography (FPLC) system as previ-
ously described by Izgu and Altinbay.12 Candida spp. majorly 
adhere to the stratum corneum layer of the vaginal epithelium 
during infections.2,3 The liposomes that we have constructed 
as panomycocin carriers were composed of lipids which are 
found in the composition of the stratum corneum layer of 
the vagina which is similar to that of the stratum corneum 
layer of the skin34 so that they would be adsorbed and mixed 
into the stratum corneum layer26 and release their contents 
where the Candida spp. localize. We have used the freeze-
thaw technique to encapsulate panomycocin in the SCLLs 
for its high efficiency in encapsulation. In this method, the 
thawing temperature is determined according to the lipid Tm 
value which is the highest among the lipids in the liposome 
structure.30 In the composition of SCLLs, ceramide is the lipid 
with the highest Tm value which is between 80°C and 90°C.35 
Since panomycocin is irreversibly inactive in this temperature 
range, we have used a modified freeze-thaw method in which 
the thawing was done at 4°C under vacuum30 in order to pre-
serve protein stability. The zeta potential values for empty and 
loaded liposomes were +22.0 and +21.4 mV, respectively, 
Figure 1 Transmission electron microscopy images.
Note: (A) empty sclls, (B) panomycocin loaded sclls.
Abbreviation: sclls, stratum corneum lipid liposomes.
Table 2 hydrodynamic size and polydispersity index values of 





empty sclls 0.0738 670.999
Panomycocin-loaded sclls 0.1500 971.544
Abbreviation: sclls, stratum corneum lipid liposomes.





Figure 2 hydrodynamic size distribution of the liposomes.
Notes: (A) empty sclls, (B) panomycocin-loaded sclls. single sharp peaks indicated monodisperse size distributions of the liposomes.
Abbreviation: sclls, stratum corneum lipid liposomes.
indicating a very low protein binding on the surface of the 
liposomes. This also indicated highly efficient separation of 
the free proteins from the loaded liposomes. The EE that we 
have obtained with the modified freeze-thaw technique was 
reasonably high (73%), as reported previously.30 The buffer 
solution of panomycocin where it was stable and bioactive 
was at pH 4. At this pH value, panomycocin is negatively 
charged.12 To enhance the EE, we have included stearylamine 
into the lipid composition of SCLLs to give liposomes a final 
positive charge.27 The zeta potential values of the empty and 
loaded SCLLs were in the positive range, which is the indica-
tion of overall positive charge on the surface of the liposomes. 
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Figure 3 Zeta potential distribution of the liposomes.
Notes: (A) empty sclls, (B) panomycocin loaded sclls. The zeta potential values of +22.0 mV and +21.4 mV for the samples respectively, indicated positively charged 
liposomes which were stable and uniformly distributed in the system.
Abbreviation: sclls, stratum corneum lipid liposomes.
We believe that, the opposite charges on SCLLs and panomy-
cocin contributed to the achievement of high encapsulation 
and loading efficiencies. TEM images of panomycocin loaded 
SCLLs, when compared to that of their empty counterparts, 
appeared as quasi-spherical particles with smaller sizes. This 
most probably is the result of the repeated freeze-thaw steps 
where the liposomes break open and re-assemble into vesicles 
during loading process. In previous studies where liposomes 
were loaded by a freeze-thaw method in a buffer solution, 
similar morphological observations were also reported.36,37 
Both types of liposomes had hydrodynamic sizes larger than 
their static sizes observed in TEM images. This is because 
in DLS analyses liposomes are dynamic, freely active in 
solution, and interacting with solvents.38 This state is con-
trary to that in transmission electron microscopy analyses 
in which drying of the samples is required which leads to 
liposome shrinkage.39 In DLS analyses we have obtained 
polydispersity index values close to 0 for both empty and 
panomycocin loaded SCLLs. This showed that the liposomes 
were monodisperse as a polydispersity index value closer 
to 0 in the range of 0–1 is the indication of monodispersity 
which is a significant factor in the efficacy of drug delivery 
and the stability studies.21,40–42 Also, an absolute value of zeta 
potential .20 mV for the liposomes shows their stability.43 
Thus, we have concluded that empty and panomycocin-
loaded SCLLs with zeta potential values of +22.0 mV 
and +21.4 mV, respectively, were stable in the colloidal 
system. An essential criterion for the active ingredient to be 
released at the target site in high amounts and in an active 
form is the lack of covalent bonds with its encapsulating 
vesicle. To investigate the presence of any irreversible inter-
actions between panomycocin and SCLLs, we have inspected 
the infrared spectra of both loaded and empty liposomes 
and observed no significant differences between the spectra 
which signaled the presence of any irreversible interactions 
after encapsulation.44 The retention of panomycocin in the 
SCLLs in buffer solution at 37°C up to 12 h was very high 
(.98%), which is the indication of high stability of SCLLs 
characterized by low leakage of active ingredient in aqueous 
medium.32 The high stability is most probably due to the long 
chain lipids with high phase transition temperatures found 
in the composition of SCLL structure, and this is also sup-
ported by the studies reporting a highly ordered structure and 
increased phase transition temperature for the lipid bilayers 





Figure 4 Fourier transform infrared spectra of the liposomes.
Notes: (A) empty sclls, (B) panomycocin-loaded SCLLs. No significant differences that indicated irreversible interactions between panomycocin and encapsulating 
liposomes were observed between the two spectra.
Abbreviation: sclls, stratum corneum lipid liposomes.
containing ceramides.35,45 We have performed a biological 
efficacy test of the liposomal panomycocin formulation on an 
in vitro model of vaginal candidiasis. Liposomal lyophilized 
powder with predetermined panomycocin quantities for each 
Candida spp., which correspond to 1× MFC value of non-
formulated pure panomycocin, was found to be inhibitory for 
all the tested strains. We have cultured the swabs from the 
tissues with no visible microbial growth onto SDA plates. 
The lack of any microbial growth on the plates at the end of 
7 days of incubation showed that the inhibitory effect of the 
formulation at quantities corresponding to 1× MFC value 
of non-formulated pure panomycocin on both Candida spp. 
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Figure 5 Time-dependent in vitro release of panomycocin from sclls in aqueous 
solution at 37°c.
Notes: Values represent the mean of three separate determinations. The standard 
error was ,0.01.
Abbreviation: sclls, stratum corneum lipid liposomes.
Figure 6 anti-candidal effect of the liposomal panomycocin on an hVe tissue model.
Notes: The tissues were infected with the clinical vaginal isolates of (A) Candida albicans and (B) Candida glabrata. Tissue inserts; 1: growth control, 2: sterility control, 
3: negative control (empty scll powder), 4: scll powder containing 8 µg panomycocin for C. albicans and 2 µg panomycocin for C. glabrata (1× MFc), 5: scll powder 
containing 12 µg panomycocin for C. albicans and 3 µg panomycocin for C. glabrata (1.5× MFc), 6: scll powder containing 16 µg panomycocin for C. albicans and 4 µg 
panomycocin for C. glabrata (2× MFc). The tissues were incubated as stated by the manufacturer (37°c and 5.0% cO2) for 48 h. similar results were obtained for the other 
two C. albicans strains.
Abbreviations: hVe, human vaginal epithelium; scll, stratum corneum lipid liposome; MFc, minimum fungicidal concentration.
was fungicidal, which was also an indication of total release 
of the encapsulated panomycocin onto the tissues. The full 
release of the active ingredient from the SCLLs was most 
likely due to the effective electrostatic interaction of the tis-
sues with the positively charged SCLLs which enabled the 
liposomes to be adsorbed onto the tissue layer effectively,46,47 
and the acidic pH of the formulation (pH 4), which enabled 
the SCLLs to be fused with the lamellar structure of the tis-
sue surface where they released their contents effectively.20 
The efficacy of the formulation was tested after storage of 
the lyophilized liposomal panomycocin at 4°C for 30 days 
under the same experimental conditions as stated in the 
“Materials and methods” section, and no significant change 
in efficacy was observed. 
It is well known that cryoprotectants are incorporated 
into the liposomal formulations to preserve their stability 
during lyophilization. The buffer solution in our liposomal 
formulation is composed of sodium phosphate and sodium 
sulfate salts and citric acid which are known for their cryopro-
tectant activities.48,49 Thus, we have not used any additional 
cryoprotectants in our formulation.
In the literature, although there are studies describing 
the use of stearylamine containing delivery systems for 
therapeutics and vaccines,27,47,50 positively charged liposomes 
may present toxicity to normal cells.51,52 The target of the 
formulation described in this study is the stratum corneum 
layer of the epithelium which is the protective layer com-
posed of dead cells. Although it is known that the SCLLs 
will integrate into the stratum corneum structure and will not 
pass to the lower layers of the epithelium,20 further studies 
to evaluate any cytotoxicity related to this formulation are 
underway in our laboratory.
As a conclusion, we have described the development 
of a liposomal formulation of an antimycotic agent. This 
is the first study in which SCLLs and a naturally produced 
protein were both used to construct a formulation intended 
for topical therapeutic applications. The liposomes that we 
have constructed from stratum corneum lipids encapsulated 
panomycocin in high amounts and were stable in aqueous 
medium. The formulation carried the active ingredient to its 
target efficiently where it released its content completely and 
in a biologically active form. The results we have obtained 
here paved the way for further preclinical trials of liposomal 





formulation of panomycocin in the development of an effec-
tive topical anti-candidal drug with improved safety and high 
activity up to 38.5°C at vaginal pHs. Long-term stability 
studies are currently underway in our laboratory.
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